Author + information
- Received August 29, 2011
- Revision received October 3, 2011
- Accepted October 5, 2011
- Published online November 1, 2011.
- Francesco Bedogni, MD⁎,
- Maria Luisa Laudisa, MD, PhD⁎,
- Samuele Pizzocri, MD⁎,
- Corrado Tamburino, MD†,
- Gian Paolo Ussia, MD†,
- Anna Sonia Petronio, MD‡,
- Massimo Napodano, MD§,
- Angelo Ramondo, MD∥,
- Patrizia Presbitero, MD¶,
- Federica Ettori, MD#,
- Gennaro Santoro, MD⁎⁎,
- Silvio Klugman, MD††,
- Federico De Marco, MD††,
- Nedy Brambilla, MD⁎ and
- Luca Testa, MD, PhD⁎,⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. Luca Testa, Department of Interventional Cardiology, Istituto Clinico S. Ambrogio, Via L. Faravelli 16, 20149 Milan, Italy
Objectives The purpose of this study was to evaluate the performance of CoreValve Revalving System (CRS) (Medtronic, Minneapolis, Minnesota) implantation in patients with failed aortic bioprostheses.
Background Transcatheter aortic valve implantation with the CRS is an effective option in high-risk patients with severe aortic stenosis. It may be an option for patients with a failed aortic bioprosthesis, especially when the risk of a surgical redo is deemed prohibitive.
Methods CRS “valve-in-valve” implantation was performed in 25 high-risk patients with a failed bioprosthesis. Their mean age was 82.4 ± 3.2 years. New York Heart Association functional classes III and IV were present in 21 and 4 patients, respectively. The logistic EuroSCORE was 31.5 ± 14.8%, whereas the Society of Thoracic Surgeons score was 8.2 ± 4.2. Patients/prostheses were divided in type A (mainly stenotic, n = 9) and type B (mainly regurgitant, n = 16).
Results The implantation success rate was 100%. In group A, the peak aortic gradient significantly decreased from 77.6 ± 21.6 mm Hg to 34.6 ± 19.4 mm Hg (p = 0.001). In all but 2 patients in group B, no significant regurgitation was observed post-implantation. No patients died during the procedure. At 30 days, there were 3 deaths (12%), 2 myocardial infarctions (8%), and 3 atrioventricular blocks requiring pacemaker implantation (12%). At a mean follow-up of 6 months, there were another death (survival rate of 84%) and a pacemaker implantation (cumulative incidence of 16%). New York Heart Association functional class improved in all patients to I and II.
Conclusions CRS implantation was feasible and effective regardless of the prevalent mode of failure. This finding may significantly affect the treatment of patients with a failed bioprosthesis deemed at a prohibitive risk for surgical redo.
Drs. Bedogni, Ussia, Petronio, Ramondo, Ettori, and Santoro are consultants for Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received August 29, 2011.
- Revision received October 3, 2011.
- Accepted October 5, 2011.
- American College of Cardiology Foundation